What is the main target of the monoclonal antibody dinutuximab?

Dinutuximab is a monoclonal antibody that specifically targets the GD2 ganglioside, which is a glycolipid found on the surface of certain cancer cells, particularly neuroblastoma cells. By binding to GD2, dinutuximab helps to facilitate the immune system's ability to identify and destroy these cancerous cells. This targeted approach can enhance the effectiveness of treatment by utilizing the body's own immune responses to combat the tumor.

The focus on GD2 is crucial, especially in the context of pediatric oncology, where neuroblastoma is a common malignant tumor. Dinutuximab works by engaging other components of the immune system, such as natural killer cells, to attack cells expressing GD2. This is especially important as GD2 is not typically present in significant amounts on normal adult tissues, reducing the potential for off-target effects and improving the therapeutic index of the treatment.

In contrast, the other listed targets such as CD20, HER2, and PD-1 represent targets for different monoclonal antibodies used in other types of cancers. For instance, CD20 is targeted by rituximab mainly in B-cell malignancies, HER2 is the target for therapies like trastuzumab in breast cancer, and PD-